Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer Full Text
Investigational New Drugs, 05/07/2012
Clinical Article
Laheru D et al. – The combination of gemcitabine and salirasib appears well–tolerated, with no alteration of salirasib exposure, and exerted clinical and PD activity in pancreatic adenocarcinoma (PDA).



